[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100444401":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":12,"locations":7,"responsibleParty":18,"collaborators":7,"id":22,"slug":23,"hasResults":24,"nctId":25,"briefTitle":26,"officialTitle":27,"acronym":7,"eligibilityCriteria":28,"healthyVolunteers":24,"sex":29,"minAge":30,"maxAge":31,"enrollmentInfo":32,"targetDuration":7,"studyType":35,"phases":7,"briefSummary":36,"conditions":37,"keywords":7,"overallStatus":39,"whyStopped":7,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":7},{"fullName":5,"class":6},"Xiangya Hospital of Central South University","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Observation","observe the association of ctDNA with efficacy of treatment",[13],{"name":14,"role":15,"phone":16,"phoneExt":7,"email":17},"Deng","CONTACT","13574888840","yogurt1015@csu.edu.cn",{"type":19,"investigatorFullName":20,"investigatorTitle":21,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"PRINCIPAL_INVESTIGATOR","dengpengbo","Attending physician","100444401","application-of-ctdna-in-the-evaluation-of-curative-effect-and-prognosis-of-sclc-patients-100444401",false,"NCT05066945","Application of ctDNA in the Evaluation of Curative Effect and Prognosis of SCLC Patients","Application of Circulating Tumor (ctDNA) in the Evaluation of Curative Effect and Prognosis of Small Cell Lung Cancer (SCLC) Patients","Inclusion Criteria:\n\n* Provision of informed consent；\n* Newly diagnosed and histological or cytological confirmed extensive stage small cell lung cancer;\n* All indicators has confirmed and allow to receive radiotherapy and chemotherapy;\n* Follow-up can be carried out and the peripheral blood samples can be collected;\n* Cooperate with the provision of clinical pathological data required by the research.\n\nExclusion Criteria:\n\n* Patients have other primary cancers;\n* Patients unable to cooperate with the study for follow-up according to the determined clinical follow-up cycle;\n* Unable to accept the judgment of curative effect evaluation by the designated methods such as CT.","ALL","18 Years","80 Years",{"count":33,"type":34},40,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate the application value of circulating tumor DNA(ctDNA) with efficacy evaluation and prognostic assessment in patients with unresectable SCLC, who were receiving radiotherapy and chemotherapy treatment.",[38],"Small Cell Lung Cancer Extensive Stage","NOT_YET_RECRUITING","2021-09-22",{"date":42,"type":43},"2021-10-04","ACTUAL",{"date":45,"type":34},"2022-01-01",{"date":47,"type":34},"2026-12-31",{"name":5,"class":6}]